Virtual Library

Start Your Search

Sruthi Kommi Reddy



Author of

  • +

    P2.15 - Treatment in the Real World - Support, Survivorship, Systems Research (Not CME Accredited Session) (ID 964)

    • Event: WCLC 2018
    • Type: Poster Viewing in the Exhibit Hall
    • Track:
    • Presentations: 1
    • Moderators:
    • Coordinates: 9/25/2018, 16:45 - 18:00, Exhibit Hall
    • +

      P2.15-24 - Comparison of Pemetrexed Administered q 3 Weeks vs q 4 Weeks as Maintenance Therapy in NSCLC: Analysis of Real World Data from a Single Institution (ID 13057)

      16:45 - 18:00  |  Presenting Author(s): Sruthi Kommi Reddy

      • Abstract
      • Slides

      Background

      Pemetrexed maintenance q 3 weeks has shown survival benefit in patients with advanced stage nonsquamous NSCLC. We sought to compare treatment outcomes in patients receiving alternate maintenance schedule ( q 4 weeks) in real-world practice.

      a9ded1e5ce5d75814730bb4caaf49419 Method

      This is a single-center, IRB-approved retrospective study of over 500 advanced stage (IIIB&IV) nonsquamous NSCLC patients receiving pemetrexed between May 1, 2011 to June 30, 2016 as standard of care. Patients who received at least two doses of maintenance pemetrexed were included in the analysis. Tumor response was assessed with CT scan imaging every 6-9 weeks. Hematologic indices, hepatic, renal function, performance status, dose changes, subsequent dosing or schedule changes, duration on therapy (discontinuation due to toxicity, switch in therapy or death) and overall survival data were obtained. Summary statistical analyses are provided for the demographic features of the patients included in this study in both. The difference between the two groups are evaluated using Fisher's Test /Chi-Square Test / Logistic regression analyses for categorical variable, and T-Test / Generalized Linear regression analyses for continuous variables. Generalized Linear regression model are applied to compare outcomes between outcomes SAS version 9.4 (SAS Institute, Cary, NC) will be used for statistical analyses. All tests were two-sided and performed at a nominal significance level of 0.05.

      4c3880bb027f159e801041b1021e88e8 Result

      138 patients were eligible to be included in the analysis. There were 90 and 48 patients who received pemetrexed q 3 weeks (group A) and q 4 weeks (group B), respectively. There were no differences in gender or ECOG performance status (PS) at baseline between the groups. Most common reasons documented for q4 week schedule are either patient preference or cumulative toxicities (lab abnormalities, poor tolerance or fatigue after induction treatment). Duration on therapy was longer in group B than in group A (282 days vs 156 days, p < 0.001). There were no differences in pre- and post-treatment changes in hemoglobin, ANC, creatinine clearance, ALT or AST levels between the two groups. There was also no difference in the change in PS between groups. Platelet count was higher at the end of therapy in group A compared to group B (p<0.01) . Survival outcomes and molecular profiling data will be presented in the meeting.

      8eea62084ca7e541d918e823422bd82e Conclusion

      Alternate q 4 week dosing schedule of pemetrexed is feasible and associated with longer time on treatment. There appears to be no difference in toxicities experienced between the two treatment schedules in this cohort.

      6f8b794f3246b0c1e1780bb4d4d5dc53

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.